Business context and reporting period
The supplied filing is Organovo Holdings, Inc.’s Form 10-Q, filed February 9, 2023, for the quarter and nine months ended December 31, 2022. This conflicts with the request metadata identifying Vivosim Labs, Inc.; the filing names Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company developing 3D human tissue models and drug-discovery programs, primarily for Crohn’s disease and ulcerative colitis.
Financial results and condition
Amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.
| Metric | Three months ended Dec. 31, 2022 | Nine months ended Dec. 31, 2022 | Prior-year comparison |
|---|---|---|---|
| Revenue | $131,000 | $208,000 | $0 in each 2021 period; revenue was royalty income under a patent license |
| Research and development expense | $1.185 million | $3.436 million | Up 28% and 57%, respectively |
| Selling, general and administrative expense | $2.305 million | $6.724 million | Down 10% and 9%, respectively |
| Operating loss | $3.359 million | $9.952 million | Prior year: $3.500 million and $9.566 million |
| Net loss | $3.264 million | $9.800 million | Prior year: $3.500 million and $9.537 million |
| Net loss per share | $0.37 | $1.13 | Prior year: $0.40 and $1.10 |
| Operating cash used | Not separately stated | $7.675 million | Prior-year nine-month use: $6.912 million |
- At December 31, 2022, cash and cash equivalents were $20.196 million, including approximately $10.0 million of U.S. Treasury bills; restricted cash was $143,000. Cash and cash equivalents were $28.675 million at March 31, 2022.
- Current assets were $21.614 million and current liabilities were $1.376 million, yielding reported working capital of approximately $20.2 million. Total assets were $25.079 million and stockholders’ equity was $22.289 million.
- Total liabilities were $2.790 million, consisting principally of operating lease liabilities; the filing reports no debt balance. Lease liabilities totaled $1.902 million.
- Cash, cash equivalents and restricted cash decreased $8.479 million during the nine months. Investing cash use was $804,000; financing cash flow was zero.
- No gross margin is reported. Revenue remains small relative to operating expenses, and the company reported operating and net losses.
Material changes versus the prior comparable period
- Royalty revenue began under the February 2022 BICO Group patent license; the company recognized $131,000 for the quarter and $208,000 for the nine-month period. The license also included a $1.5 million upfront payment recognized in February 2022, not in the periods shown.
- R&D costs increased as headcount and research activity expanded. Management attributed the nine-month increase mainly to higher personnel, laboratory and facility costs.
- SG&A declined primarily because legal and general corporate costs fell after litigation was settled in fiscal 2022; personnel and stock-based compensation costs increased.
- Interest income increased with higher rates and investments. The company also recorded a $123,000 nine-month loss on equity securities.
Outlook, risks and unusual items
- Management forecast fiscal 2023 operating expenses of $12 million to $14 million and stated that available cash was expected to fund operations for at least 12 months from the filing’s assessment. It also said additional capital would be needed to execute its longer-term drug-development plans; future financing availability and terms are uncertain.
- The company expects to continue increasing R&D headcount and activity, with associated expense growth. Its drug-discovery strategy is early-stage and unproven, and development, regulatory approval and commercialization involve substantial uncertainty.
- On February 8, 2023, Organovo signed a binding term sheet to negotiate acquisition of Metacrine’s FXR program for total cash payments of $4 million. The proposed transaction remained subject to due diligence and a definitive agreement; the parties expected to close before March 31, 2023.
- Cash burn, dependence on future financing, potential dilution, uncertain strategic partnerships, reliable access to human cells, intellectual-property risks, and COVID-19 or broader supply-chain disruptions are material risks identified in the filing.
- Prior patent litigation with BICO Group was settled in February 2022. The company reported no accrual for loss contingencies during the periods presented, while noting that legal outcomes can be uncertain.
Important facts for investors to verify
- Confirm the issuer and reporting period: the supplied metadata says Vivosim Labs and 2022 Q3, but the filing is Organovo Holdings’ quarter ended December 31, 2022.
- Assess cash runway against the reported operating burn, planned R&D spending, and the contingent $4 million Metacrine transaction; the filing’s 12-month liquidity statement depends on management’s operating-plan assumptions.
- Review the BICO royalty arrangement, including future royalty terms and whether royalty receipts can meaningfully offset development spending.
- Check the status and funding of the Metacrine transaction, and whether the contemplated payment was made after the reporting date.
- Consider potential dilution: 8,714,590 common shares were outstanding at December 31, 2022, with equity awards and plan reserves also disclosed; the company had approximately $28.3 million of remaining ATM capacity.